Diabetes

TrkB agonist prodrug R13 (R13) is a prodrug form of the tropomyosin-related kinase B (TrkB) activator 7,8-dihydroxyflavone.

Sergliflozin A is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; Ki = 2.39 nM for the human transporter) and an active metabolite of sergliflozin etabonate.

9(10)-Nitrooleate is a mixture of the nitroalkene endogenous lipid signaling molecules 9-nitrooleate.

GLP-1 (7-13) (human, mouse, rat, bovine) (trifluoroacetate salt) is a peptide fragment of the endogenous incretin hormone GLP-1.

Glucagon-like peptide 1 (GLP-1) (7-15) is a peptide fragment of the endogenous incretin hormone GLP-1.

Glucagon-like peptide 1 (GLP-1) (28-36) amide is a peptide and an active metabolite of the endogenous GLP-1R agonist GLP-1 (7-36) amide.

Glucagon-like peptide 1 (GLP-1) (7-17) is a peptide fragment of the endogenous incretin hormone GLP-1 .

Semaglutide main chain (9-37) is a peptide starting material in the synthesis of semaglutide.

Taspoglutide is an agonist of the glucagon-like peptide 1 receptor (GLP-1R; Ki = 1.1 nM for the human receptor).

Glucagon-like peptide 1 (GLP-1) (7-36) acid is a derivative of the hormone and GLP-1 receptor (GLP-1R) agonist GLP-1 (7-36) amide.

KBP-066 is a dual amylin and calcitonin (CT) receptor agonist.

Liraglutide is a potent agonist of the glucagon-like peptide 1 (GLP-1) receptor and a synthetic derivative of GLP-1 (7-37) that contains a palmitic acid group.

Dapiglutide is a dual glucagon-like peptide 1 receptor (GLP-1R) and GLP-2R agonist.

SAR441255 is a peptide triple agonist of the glucagon-like peptide 1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).

Glucose-dependent Insulinotropic Polypeptide (GIP) (1-42) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion.

Glucose-dependent Insulinotropic Polypeptide (GIP) (human) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose.